
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. has recently enhanced its financial foundation through successful equity financings and option exercises, with financing income significantly increasing to $284K for the quarter and $611K year-to-date, up from $85K and $144K, respectively. The company is strategically positioning itself for growth ahead of its full product launches planned for the U.S. and EU between 2026 and 2028, supported by a strengthened commercial team and an effective logistics partnership to ensure operational readiness. Additionally, the growing positive feedback from healthcare providers regarding the LIBERTY Endovascular Robotic System suggests a strong market potential, reinforcing the outlook for accelerated growth and justifying a premium valuation in anticipation of its upcoming product launches.
Bears say
Microbot Medical faces a multitude of risks that significantly contribute to a negative outlook on its stock, including potential delays in the commercialization of its LIBERTY Endovascular Robotic System and challenges in expanding into neuro and cardio markets. The company is also hindered by a lack of near-term profitability and reimbursement issues, which could erode hospital margins linked to existing procedural codes for its devices. Additionally, the absence of data from randomized controlled trials further complicates its ability to secure necessary approvals and achieve sustainable commercial uptake.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares